Granulocyte-colony stimulating factor therapy in drug-induced agranulocytosis.
Drug-induced agranulocytosis in the outpatient setting is a rare but potentially fatal adverse effect of many classes of medications. Five patients with this disorder presented to Yale-New Haven (Conn) Hospital during 1990 through 1992. Three patients treated with granulocyte-colony stimulating factor and two patients treated with routine care were studied for relevant clinical outcomes. Treatment with granulocyte-colony stimulating factor was associated with a shorter duration of neutropenia and a decreased length of hospital stay, consistent with recent case reports. Despite the high cost of the drug, treatment with granulocyte-colony stimulating factor was found to be cost-effective for patients with uncomplicated drug-induced agranulocytosis.
Mani
S
S
Department of Internal Medicine, Yale University School of Medicine, New Haven, Conn.
Barry
M
M
Concato
J
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000380:Agranulocytosis / Q000139:chemically induced / Q000188:drug therapy*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D016179:Granulocyte Colony-Stimulating Factor